Efficacy of tyrosine kinase inhibitors in Ph-like acute lymphoblastic leukemia harboring ABL-class rearrangements
Journal article published in 2019 by
Ilaria Tanasi,
Ibrahima Ba 
,
Nicolas Sirvent,
Thorsten Braun,
Wendy Cuccuini,
Paola Ballerini,
Nicolas Duployez ,
Aline Tanguy-Schmidt,
Jérôme Tamburini ,
Sébastien Maury,
Eric Doré,
Chantal Himberlin,
Cédric Duclos,
Patrice Chevallier,
Philippe Rousselot
and other authors.
,
Nicolas Sirvent,
Thorsten Braun,
Wendy Cuccuini,
Paola Ballerini,
Nicolas Duployez ,
Aline Tanguy-Schmidt,
Jérôme Tamburini ,
Sébastien Maury,
Eric Doré,
Chantal Himberlin,
Cédric Duclos,
Patrice Chevallier,
Philippe Rousselot
and other authors.
Distributing this paper is prohibited by the publisher
Full text: Unavailable
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 
Abstract
Abstract Tanasi et al present a prospective strategy for identifying patients with Philadelphia-like acute lymphoblastic leukemia, demonstrating the efficacy of early introduction of tyrosine kinase inhibitors in improving outcomes.